Stockscreener 앱 받기
332.42
0.08%
0.25
시간 외 거래:
332.42
전일 마감가:
$332.17
열려 있는:
$332.19
하루 거래량:
346.41K
Relative Volume:
0.35
시가총액:
$13.05B
수익:
$1.40B
순이익/손실:
$177.69M
주가수익비율:
73.49
EPS:
4.5234
순현금흐름:
$174.93M
1주 성능:
+0.40%
1개월 성능:
-1.12%
6개월 성능:
+31.59%
1년 성능:
+22.10%
1일 변동 폭
$332.08
$333.32
1주일 범위
$328.86
$333.32
52주 변동 폭
$221.26
$362.41
Penumbra Inc Stock (PEN) Company Profile
명칭
Penumbra Inc
전화
(510) 995-2486
주소
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
332.42 | 13.04B | 1.40B | 177.69M | 174.93M | 4.5234 |
ABT
Abbott Laboratories
|
101.56 | 175.59B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
341.24 | 132.47B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.10 | 113.14B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.61 | 94.85B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
78.20 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-12-11 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-11-18 | 개시 | Wells Fargo | Underweight |
| 2025-10-08 | 업그레이드 | Needham | Hold → Buy |
| 2025-09-02 | 개시 | Evercore ISI | Outperform |
| 2025-03-14 | 개시 | BofA Securities | Buy |
| 2025-01-21 | 개시 | UBS | Buy |
| 2024-12-17 | 개시 | Oppenheimer | Outperform |
| 2024-12-11 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-09-18 | 개시 | Stifel | Buy |
| 2024-09-03 | 개시 | Leerink Partners | Outperform |
| 2024-07-31 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-07-31 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-02-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-09-06 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-07-19 | 개시 | Robert W. Baird | Outperform |
| 2023-03-29 | 다운그레이드 | Needham | Buy → Hold |
| 2023-01-30 | 개시 | Piper Sandler | Overweight |
| 2022-11-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-10-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-09-09 | 업그레이드 | Needham | Hold → Buy |
| 2022-07-18 | 개시 | RBC Capital Mkts | Outperform |
| 2022-04-19 | 개시 | Deutsche Bank | Buy |
| 2022-03-08 | 개시 | Needham | Hold |
| 2021-09-16 | 개시 | Truist | Buy |
| 2021-06-04 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-12-16 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-10-07 | 재개 | Canaccord Genuity | Buy |
| 2020-09-29 | 개시 | BTIG Research | Buy |
| 2020-09-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-05-30 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-05-21 | 개시 | William Blair | Outperform |
| 2018-10-29 | 재개 | BofA/Merrill | Buy |
| 2018-10-08 | 개시 | RBC Capital Mkts | Outperform |
| 2018-02-21 | 개시 | William Blair | Outperform |
| 2018-01-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2015-11-30 | 재확인 | Canaccord Genuity | Buy |
| 2015-10-13 | 개시 | Wells Fargo | Outperform |
모두보기
Penumbra Inc 주식(PEN)의 최신 뉴스
Understanding Momentum Shifts in (PEN) - Stock Traders Daily
Boston Scientific’s $14.9 Billion Bet: The Strategic "Homecoming" to Neurovascular Dominance - FinancialContent
Consolidation Fever: Boston Scientific’s $14.9 Billion Bet on Penumbra Signals New Era in MedTech M&A - FinancialContent
Did STORM-PE’s Strong Functional Outcomes Just Shift Penumbra's (PEN) Investment Narrative? - simplywall.st
Penumbra (PEN) to Release Quarterly Earnings on Wednesday - MarketBeat
Penumbra Inc stock (US70975L1070): Why its neurovascular leadership matters more now for investors - AD HOC NEWS
Penumbra Presents STORM-PE 90-day Results at SIR - dicardiology.com
Study backs Penumbra computer-assisted thrombectomy - MassDevice
Penumbra (PEN) Reports Positive Outcomes from STORM-PE Trial - GuruFocus
Aug PreEarnings: What is the long term forecast for Penumbra Inc stock2026 WrapUp & Weekly High Momentum Picks - baoquankhu1.vn
Penumbra trial shows improved outcomes for pulmonary embolism - Investing.com
Penumbra trial shows improved outcomes for pulmonary embolism By Investing.com - Investing.com Canada
New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients - PR Newswire
Baillie Gifford & Co. Sells 32,221 Shares of Penumbra, Inc. $PEN - MarketBeat
3 Reasons Why Growth Investors Shouldn't Overlook Penumbra (PEN) - Yahoo Finance
Are OMEX, PEN, SNCY, CWAN Obtaining Fair Deals for their Shareholders? - Sahm
Penumbra Sale To Boston Scientific Sparks Review Of Deal Value - Yahoo Finance
Penumbra, Inc. (PEN) Stock Forecasts - Yahoo Finance
Penumbra, Inc. (PEN) stock price, news, quote and history - Yahoo Finance Australia
Fidelity Stock Selector Small Cap Fund's Penumbra Inc(PEN) Holding History - GuruFocus
Penumbra Investor Alert: Kahn Swick & Foti Investigates Proposed Sale - National Today
Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc.PEN - The AI Journal
Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc.PEN - FinancialContent
Penumbra, Inc. (PEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Penumbra (NYSE:PEN): Strongest Q4 Results from the Medical Devices & SuppliesCardiology, Neurology, Vascular Group - Yahoo Finance
Citi Maintains Penumbra(PEN.US) With Hold Rating, Maintains Target Price $374 - Moomoo
Penumbra (NYSE:PEN) Director Sells $32,822.00 in Stock - MarketBeat
Grewal Harpreet, Penumbra director, sells $32,822 in stock - Investing.com UK
Grewal Harpreet, Penumbra director, sells $32,822 in stock By Investing.com - Investing.com South Africa
Penumbra (NYSE: PEN) director sells 100 shares under Rule 10b5-1 plan - Stock Titan
Penumbra (PEN) down 1.6% since last earnings report: Can it rebound? - MSN
JP Morgan Maintains Penumbra (PEN) Neutral Recommendation - MSN
Penumbra, Inc. (PEN) latest stock news and headlines - Yahoo Finance UK
PEN PE Ratio & Valuation, Is PEN Overvalued - Intellectia AI
Penumbra, Inc. (PEN.MX) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
SG Americas Securities LLC Has $3.46 Million Stake in Penumbra, Inc. $PEN - MarketBeat
[144] Penumbra Inc SEC Filing - Stock Titan
Boston Scientific (NYSE: BSX) to Acquire Penumbra; $374/Share Cash-or-Stock Deal - Stock Titan
Boston Scientific (NYSE: BSX) to acquire Penumbra in $374/share deal - Stock Titan
Allspring Global Investments Holdings LLC Sells 6,471 Shares of Penumbra, Inc. $PEN - MarketBeat
Are EHAB, SLAB, PEN, SKYT Obtaining Fair Deals for their Shareholders? - Sahm
Aug Macro: Is Penumbra Inc impacted by rising ratesWeekly Trade Summary & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-SLAB, PEN, SKYT, and EHAB - The Malaysian Reserve
Boston Scientific (NYSE: BSX) to Acquire Penumbra in $374/Share Deal - Stock Titan
Dow Update: What is the long term forecast for Penumbra Inc stockGlobal Markets & Verified Entry Point Detection - baoquankhu1.vn
Assessing Penumbra (PEN) Valuation As Shares Trade On A High P/E Multiple - Yahoo Finance
Vanguard disaggregates holdings; reports 0 shares in Penumbra (PEN) - Stock Titan
Penumbra (PEN) Down 1.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Reasons to Keep Penumbra Shares in Your Portfolio at This Time - Bitget
Penumbra Inc (PEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.40%
0.00%
자본화:
|
볼륨(24시간):